Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support

Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384 · see citing works

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates

Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154 · see citing works

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P. A., Rutherford, N. K., Martin, J. M., Frydenberg, M., Ramdave, S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,067 · see citing works

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,665 · see citing works

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170 · see citing works

Adaptive Lasso for Cox's proportional hazards model

Zhang, H., & Lu, W.-B. (2007) · Biometrika · doi:10.1093/biomet/asm037 · Cited by 675 · see citing works

Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626 · see citing works

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Halabi, S., Lin, C., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 479 · see citing works

DNA Damage-Mediated Induction of a Chemoresistant Niche

Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428 · see citing works

Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

Dietlein, M., Kobe, C., Kuhnert, G., Stockter, S., Fischer, T. H., Schomäcker, K., Schmidt, M., Dietlein, F., Zlatopolskiy, B. D., Krapf, P., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0866-0 · Cited by 355 · see citing works

Implication of cell kinetic changes during the progression of human prostatic cancer.

Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L. J., Johnson, D. E., Veltri, R. W., Walsh, P. C., & Isaacs, J. T. (1995) · PubMed · Cited by 342 · see citing works

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

Kattan, M. W., Hess, K. R., Amin, M. B., Lü, Y., Moons, K. G. M., Gershenwald, J. E., Gimotty, P. A., Guinney, J., Halabi, S., Lazar, A. J., et al. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21339 · Cited by 334 · see citing works

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Heck, M. M., Tauber, R., Schwaiger, S., Retz, M. M., D’Alessandria, C., Maurer, T., Gafita, A., Wester, H., Gschwend, J. E., Weber, W., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.016 · Cited by 299 · see citing works

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis

Bravaccini, S., Puccetti, M., Bocchini, M., Ravaioli, S., Celli, M., Scarpi, E., Giorgi, U. D., Tumedei, M. M., Raulli, G., Cardinale, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22594-1 · Cited by 188 · see citing works

Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

Emmett, L., Crumbaker, M., Ho, B., Willowson, K. P., Eu, P., Ratnayake, L., Epstein, R. J., Blanksby, A., Horvath, L. G., Guminski, A. D., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.014 · Cited by 187 · see citing works

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

Halabi, S., Lin, C., Small, E. J., Armstrong, A. J., Kaplan, E. B., Petrylak, D. P., Sternberg, C. N., Shen, L., Oudard, S. M., Bono, J. S. D., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt280 · Cited by 166 · see citing works

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Ferdinandus, J., Violet, J. A., Sandhu, S. K., Hicks, R. J., Kumar, A. S. R., Iravani, A., Kong, G., Akhurst, T. J., Thang, S. P., Murphy, D. G., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04723-z · Cited by 165 · see citing works

Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer

Freitag, M. T., Radtke, J. P., Hadaschik, B. A., Kopp‐Schneider, A., Eder, M., Kopka, K., Haberkorn, U., Roethke, M. C., Schlemmer, H., & Afshar‐Oromieh, A. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3206-3 · Cited by 163 · see citing works

Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer

Woythal, N., Arsenić, R., Kempkensteffen, C., Miller, K., Janssen, J.-C., Huang, K., Makowski, M. R., Brenner, W., & Prasad, V. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.195172 · Cited by 162 · see citing works

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT

Gafita, A., Bieth, M., Krönke, M., Tetteh, G., Navarro, F., Wang, H., Günther, E., Menze, B. H., Weber, W., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224055 · Cited by 127 · see citing works

Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity

Current, K., Meyer, C. A. L., Magyar, C. E., Mona, C. E., Almajano, J., Slavik, R., Stuparu, A. D., Cheng, C., Dawson, D. W., Radu, C. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1485 · Cited by 124 · see citing works

Novel therapies are changing treatment paradigms in metastatic prostate cancer

Powers, E., Karachaliou, G. S., Kao, C., Harrison, M. R., Hoimes, C. J., George, D. J., Armstrong, A. J., & Zhang, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00978-z · Cited by 123 · see citing works

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy

Ruigrok, E. A. M., van Vliet, N., Dalm, S. U., de Blois, E., van Gent, D. C., Haeck, J. C., de Ridder, C., Stuurman, D. C., Konijnenberg, M., van Weerden, W. M., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05057-6 · Cited by 104 · see citing works

Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair–Associated Genes

Kratochwil, C., Giesel, F. L., Heußel, C. P., Kazdal, D. N., Endris, V., Nientiedt, C., Bruchertseifer, F., Kippenberger, M., Rathke, H. G., Leichsenring, J., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234559 · Cited by 91 · see citing works

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Ahmadzadehfar, H., Schlolaut, S., Fimmers, R., Yordanova, A., Hirzebruch, S., Schlenkhoff, C. D., Gaertner, F. C., Awang, Z. H., Hauser, S., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21600 · Cited by 88 · see citing works

Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer

Ceci, F., Bianchi, L., Borghesi, M., Polverari, G., Farolfi, A., Briganti, A., Schiavina, R., Brunocilla, E., Castellucci, P., & Fanti, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04505-2 · Cited by 71 · see citing works

UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu‐PSMA‐617 and docetaxel vs docetaxel in metastatic hormone‐naïve prostate cancer (clinical trial protocol)

Dhiantravan, N., Emmett, L., Joshua, A. M., Pattison, D. A., Francis, R. J., Williams, S., Sandhu, S. K., Davis, I. D., Vela, I., Neha, N., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15384 · Cited by 64 · see citing works

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study

Gafita, A., Fendler, W. P., Wang, H., Sandhu, S. K., Weber, M., Esfandiari, R., Calais, J., Rauscher, I., Rathke, H. G., Tauber, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.004 · Cited by 62 · see citing works

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Westgeest, H. M., Groot, C. A. U., van Moorselaar, R. J. A., de Wit, R., van den Bergh, A. C. M., Coenen, J. L. L. M., Beerlage, H. P., Hendriks, M. P., Bos, M. M. E. M., van den Berg, P., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.09.008 · Cited by 59 · see citing works

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Gafita, A., Heck, M. M., Rauscher, I., Tauber, R., Cala, L., Franz, C., D’Alessandria, C., Retz, M. M., Weber, W., & Eiber, M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.240242 · Cited by 59 · see citing works

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

von Eyben, F. E., Singh, A., Zhang, J., Nipsch, K., Meyrick, D. P., Lenzo, N. P., Kairemo, K., Joensuu, T. K., Virgolini, I. J., Soydal, Ç., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26789 · Cited by 50 · see citing works

Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging

Ma, T. M., Gafita, A., Shabsovich, D., Juarez, J. E., Grogan, T., Thin, P., Armstrong, W. R., Sonni, I., Nguyen, K., Lok, V. M., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.01.006 · Cited by 22 · see citing works

PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0

Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J. B., Calais, J., Ceci, F., Cho, S. Y., Fanti, S., Giesel, F. L., Goffin, K. E., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06089-w · Cited by 438 · see citing works

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B. A., Calais, J., Giesel, F. L., Reiter, R. E., Maurer, T., Heck, M. M., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.02.002 · Cited by 326 · see citing works

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P. J., Lindenberg, L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06255-8 · Cited by 326 · see citing works

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S.-T., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00605-2 · Cited by 296 · see citing works

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer

Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-024-00900-z · Cited by 158 · see citing works

Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

Gafita, A., Rauscher, I., Weber, M., Hadaschik, B. A., Wang, H., Armstrong, W. R., Tauber, R., Grogan, T., Czernin, J. G., Rettig, M. B., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263072 · Cited by 156 · see citing works

Radiotheranostics in oncology: Making precision medicine possible

Aboagye, E. O., Barwick, T. D., & Haberkorn, U. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21768 · Cited by 131 · see citing works

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.04.002 · Cited by 130 · see citing works

Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer

Gafita, A., Djaileb, L., Rauscher, I., Fendler, W. P., Hadaschik, B. A., Rowe, S. P., Herrmann, K., Calais, J., Rettig, M. B., Eiber, M., et al. (2023) · Radiology · doi:10.1148/radiol.222148 · Cited by 124 · see citing works

Quantitative ⁶⁸ Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷ Lu-PSMA-617 (VISION Trial)

Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology · doi:10.1148/radiol.233460 · Cited by 119 · see citing works

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria

Gafita, A., Rauscher, I., Fendler, W. P., Murthy, V., Wang, H., Armstrong, W. R., Herrmann, K., Weber, W., Calais, J., Eiber, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05882-x · Cited by 101 · see citing works

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials

Jang, A., Kendi, A. T., & Sartor, O. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231157632 · Cited by 101 · see citing works

Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Karpinski, M. J., Hüsing, J., Claassen, K., Möller, L., Kajüter, H., Oesterling, F., Grünwald, V., Umutlu, L., Kleesiek, J., Telli, T., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00326-7 · Cited by 94 · see citing works

Using PSMA imaging for prognostication in localized and advanced prostate cancer

Roberts, M. J., Maurer, T., Perera, M., Eiber, M. J., Hope, T. A., Ost, P., Siva, S., Hofman, M. S., Murphy, D. G., Emmett, L., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00670-6 · Cited by 93 · see citing works

[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature

Evangelista, L., Maurer, T., van der Poel, H. G., Alongi, F., Kunikowska, J., Laudicella, R., Fanti, S., & Hofman, M. S. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.03.004 · Cited by 89 · see citing works

Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?

Gafita, A., Wang, H., Robertson, A., Armstrong, W. R., Zaum, R., Weber, M., Yagubbayli, F., Kratochwil, C., Grogan, T., Nguyen, K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261906 · Cited by 84 · see citing works

177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy

John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A. O. W., Wilson, P., Niman, R., Ayers, M., Poole, A., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264677 · Cited by 75 · see citing works

Theranostics - a sure cure for cancer after 100 years?

Song, Y., Zou, J., Castellanos, E., Matsuura, N., Ronald, J. A., Shuhendler, A. J., Weber, W., Gilad, A. A., Müller, C., Witney, T. H., et al. (2024) · Theranostics · doi:10.7150/thno.96675 · Cited by 73 · see citing works

Evaluation of177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Pathmanandavel, S., Crumbaker, M., Ho, B., Yam, A. O. W., Wilson, P., Niman, R., Ayers, M., Sharma, S., Hickey, A. J., Eu, P., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264398 · Cited by 68 · see citing works

Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics

Liberini, V., Laudicella, R., Balma, M., Nicolotti, D. G., Buschiazzo, A., Grimaldi, S., Lorenzon, L., Bianchi, A., Peano, S., Bartolotta, T. V., et al. (2022) · European Radiology Experimental · doi:10.1186/s41747-022-00282-0 · Cited by 66 · see citing works

Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis

Hotta, M., Gafita, A., Czernin, J. G., & Calais, J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263441 · Cited by 63 · see citing works

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Staniszewska, M., Costa, P. F., Eiber, M., Klose, J. M., Wosniack, J., Reis, H., Szarvas, T., Hadaschik, B. A., Lückerath, K., Herrmann, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147431 · Cited by 61 · see citing works

PSMA PET Tumor–to–Salivary Gland Ratio to Predict Response to [ 177 Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study

Hotta, M., Gafita, A., Murthy, V., Benz, M., Sonni, I., Burger, I. A., Eiber, M., Emmett, L., Farolfi, A., Fendler, W. P., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265242 · Cited by 55 · see citing works

Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens

Yazdani, E., Geramifar, P., Ziarati, N. K., Sadeghi, M., Amini, P., & Rahmim, A. (2024) · Diagnostics · doi:10.3390/diagnostics14020181 · Cited by 55 · see citing works

Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

Patell, K., Kurian, M., Garcia, J. A., Mendiratta, P., Barata, P. C., Jia, A. Y., Spratt, D. E., & Brown, J. R. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213892 · Cited by 54 · see citing works

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Emmett, L., John, N., Pathmanandavel, S., Counter, W., Ayers, M., Sharma, S., Agrawal, S., Poole, A., Hovey, E. J., Pranavan, G., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156392 · Cited by 45 · see citing works

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man

Privé, B. M., Derks, Y. H. W., Rosar, F., Franssen, G. M., Peters, S. M. B., Khreish, F., Bartholomä, M. D., Maus, S., Gotthardt, M., Laverman, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05661-0 · Cited by 45 · see citing works

Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond

Gafita, A., Marcus, C. V., Kostos, L. K., Schuster, D. M., Calais, J., & Hofman, M. S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350946 · Cited by 44 · see citing works

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

Hartrampf, P. E., Hüttmann, T., Seitz, A. K., Kübler, H. R., Serfling, S. E., Schlötelburg, W., Michalski, K., Rowe, S. P., Pomper, M. G., Buck, A. K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06281-6 · Cited by 43 · see citing works

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

Neubauer, M. C., Nicolas, G. P., Bauman, A., Fani, M., Nitzsche, E. U., Afshar‐Oromieh, A., Forrer, F., Rentsch, C. A., Stenner, F., Templeton, A. J., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06536-2 · Cited by 40 · see citing works

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

Herrmann, K., Gafita, A., Bono, J. S. D., Sartor, O., Chi, K. N., Krause, B. J., Rahbar, K., Tagawa, S. T., Czernin, J., El-Haddad, G. E., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102862 · Cited by 37 · see citing works

DITTO: A Visual Digital Twin for Interventions and Temporal Treatment Outcomes in Head and Neck Cancer

Wentzel, A., Kamel, S., Zhang, X., Canahuate, G. M., Fuller, C. D., & Marai, G. E. (2024) · IEEE Transactions on Visualization and Computer Graphics · doi:10.1109/tvcg.2024.3456160 · Cited by 35 · see citing works

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Hartrampf, P. E., Seitz, A. K., Weinzierl, F., Serfling, S. E., Schirbel, A., Rowe, S. P., Kübler, H. R., Buck, A. K., & Werner, R. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05853-2 · Cited by 33 · see citing works

Prediction of Resistance to 177 Lu-PSMA Therapy by Assessment of Baseline Circulating Tumor DNA Biomarkers

Sartor, O. A., Ledet, E. M., Huang, M., Schwartz, J., Lieberman, A., Lewis, B. E., Layton, J. L., Barata, P. C., Jang, A., Hawkins, M. E., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266167 · Cited by 32 · see citing works

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer

Unterrainer, L. M., Calais, J., & Bander, N. H. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-081522-031439 · Cited by 32 · see citing works

Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis

Ninatti, G., Scilipoti, P., Pini, C., Barletta, F. M., Longoni, M., Gelardi, F., Sollini, M., Gandaglia, G., Sathekge, M. M., Montorsi, F., et al. (2025) · Theranostics · doi:10.7150/thno.106574 · Cited by 32 · see citing works

PSMA Radioligand Therapy in Prostate Cancer

Almeida, L. S., Etchebehere, E., Megías, I. G., Terán, A. K. C., Hadaschik, B. A., Colletti, P. M., Herrmann, K., Giammarile, F., & Bolton, R. C. D. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004919 · Cited by 32 · see citing works

Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives

Bauckneht, M., Ciccarese, C., Laudicella, R., Mosillo, C., D’Amico, F., Anghelone, A., Strusi, A., Beccia, V., Sergio Bracarda, A., Fornarini, G., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102698 · Cited by 30 · see citing works

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy

Widjaja, L., Werner, R. A., Krischke, E., Christiansen, H., Bengel, F. M., Bogdanova, N. V., & Derlin, T. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05974-8 · Cited by 30 · see citing works

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective

Hoffman, A., & Amiel, G. E. (2023) · Cancers · doi:10.3390/cancers15133402 · Cited by 30 · see citing works

Radioligand Therapy in Cancer Management: A Global Perspective

Ninatti, G., Lee, S. T., & Scott, A. M. (2025) · Cancers · doi:10.3390/cancers17213412 · Cited by 29 · see citing works

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review

Heidegger, I. M., Kesch, C. V., Kretschmer, A., Tsaur, I., Ceci, F., Massimo Valerio, A., Derya Tilki, A., Marra, G., Preißer, F., Fankhauser, C. D., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081922 · Cited by 29 · see citing works

AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer

Vanwelkenhuyzen, J. P., Bos, E. V., Bruwaene, S. V., Lesage, K., Maes, A., Üstmert, S., Lavent, F., Beels, L., Grönberg, H., Ost, P., et al. (2023) · European Urology Open Science · doi:10.1016/j.euros.2023.05.008 · Cited by 29 · see citing works

Multi-view radiomics and deep learning modeling for prostate cancer detection based on multi-parametric MRI

Li, C., Deng, M., Zhong, X., Ren, J., Chen, X., Chen, J., Xiao, F., & Xu, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1198899 · Cited by 28 · see citing works

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells

Sommer, U. J., Siciliano, T., Ebersbach, C., Beier, A.-M. K., Stope, M. B., Jöhrens, K., Baretton, G. B., Borkowetz, A., Thomas, C., & Erb, H. H. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031046 · Cited by 27 · see citing works

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Gupta, S., Halabi, S., Yang, Q., Roy, A., Tubbs, A., Gore, Y., George, D. J., Nanus, D. M., Antonarakis, E. S., Danila, D. C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3233 · Cited by 27 · see citing works

Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy

Liu, Y., Tang, H., Song, T., Xu, M., Chen, J., Cui, X.-Y., Han, Y., Li, Z., & Liu, Z. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06230-3 · Cited by 26 · see citing works

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy

Calais, J., & Czernin, J. G. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263159 · Cited by 26 · see citing works

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Hong, S., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J. C., Bergstrom, C. P., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06718-6 · Cited by 26 · see citing works

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

Kostos, L. K., Buteau, J. P., Hofman, M. S., & Azad, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231179309 · Cited by 25 · see citing works

Prognostic Value of PSMA PET/CT in Prostate Cancer

Lawal, I. O., Ndlovu, H., Kgatle, M., Mokoala, K. M. G., & Sathekge, M. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.003 · Cited by 25 · see citing works

Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis

van der Sar, E. C. A., Kühr, A. J. S., Ebbers, S. C., Henderson, A., de Keizer, B., Lam, M. G. E. H., & Braat, A. J. A. T. (2022) · Biomedicines · doi:10.3390/biomedicines10071575 · Cited by 25 · see citing works

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received177Lu-PSMA-617: Importance of18F-FDG–Avid Discordant Findings

Demirci, R. A., Ghodsi, A., Gulati, R., Behnia, F., Nelson, P. S., Cheng, H. H., Yezefski, T., Haffner, M. C., Hawley, J. E., Montgomery, B., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268167 · Cited by 24 · see citing works

Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer

Calais, J., Eulau, S. M., Gardner, L., Hauke, R. J., Kendi, A. T., Shore, N. D., & Zhao, S. Q. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102524 · Cited by 23 · see citing works

Initial Experience with [ 177 Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction

Gafita, A., Voter, A. F., Shesadri, S., Spitz, A. N., Marshall, C. H., Rowe, S. P., Markowski, M. C., Pomper, M. G., Civelek, A. C., Carducci, M. A., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267723 · Cited by 23 · see citing works

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma

Wang, X., Lu, Y., Liu, Z., Zhang, Y., He, Y., Sun, C., Li, L., Zhai, Q.-L., Meng, B., Ren, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.813031 · Cited by 23 · see citing works

Eligibility for 177 Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68 Ga-PSMA-11 and 99m Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

Cook, G., Wong, W., Sanghera, B., Mangar, S. A., Challapalli, A., Bahl, A. K., Bassett, P., Leaning, D. J., & Schmidkonz, C. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264296 · Cited by 23 · see citing works

Impact of PSMA PET on Prostate Cancer Management

Weiner, A. B., Agrawal, R., Valle, L., Sonni, I., Kishan, A. U., Rettig, M. B., Raman, S. S., Calais, J., Boutros, P. C., & Reiter, R. E. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01181-9 · Cited by 22 · see citing works

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study

Calderoni, L., Maietti, E., Farolfi, A., Mei, R., Louie, K. S., Groaning, M., & Fanti, S. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264964 · Cited by 21 · see citing works

From biology to the clinic — exploring liver metastasis in prostate cancer

Ni, X., Yu, W., Li, X., Pan, J., Fang, B., Zhang, T., Lu, Y., Ye, D., & Zhu, Y. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00875-x · Cited by 21 · see citing works

Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Gutsche, R., Gülmüs, G., Mottaghy, F. M., Gärtner, F., Essler, M., von Mallek, D., Ahmadzadehfar, H., Lohmann, P., & Heinzel, A. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1234853 · Cited by 20 · see citing works

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients

Slootbeek, P. H. J., Velez, M. V. L., Privé, B. M., van der Doelen, M. J., Kloots, I. S. H., Naga, S. P., Onstenk, H. E., Nagarajah, J., Westdorp, H., van Oort, I. M., et al. (2024) · Theranostics · doi:10.7150/thno.96322 · Cited by 20 · see citing works

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study

Banda, A., Privé, B. M., Allach, Y., Uijen, M. J. M., Peters, S. M. B., Loeff, C. C., Gotthardt, M., Muselaers, S., Witjes, J. A., van Oort, I. M., et al. (2022) · Cancers · doi:10.3390/cancers15010297 · Cited by 20 · see citing works

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues

Hoshi, S., Yaginuma, K., Meguro, S., Onagi, A., Matsuoka, K., Hata, J., Sato, Y., Akaihata, H., Kataoka, M., Ogawa, S., et al. (2023) · Current Oncology · doi:10.3390/curroncol30080529 · Cited by 20 · see citing works

The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., Haller, B., D’Alessandria, C., Weber, W. A., Eiber, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265346 · Cited by 19 · see citing works

Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC

Telli, T., Lopes, L. R., Karpinski, M. J., Pabst, K. M., Grünwald, V., Shi, K., Hadaschik, B., Kesch, C., Umutlu, L., Herrmann, K., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07198-y · Cited by 19 · see citing works

Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [ 177 Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials

Kashyap, R. K., Buteau, J. P., Bressel, M., Eifer, M., Bollampally, N., Jackson, P. A., McIntosh, L., Sandhu, S. K., & Hofman, M. S. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269640 · Cited by 19 · see citing works

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Kim, M., Seifert, R., Fragemann, J., Kersting, D., Murray, J., Jonske, F., Pomykala, K. L., Egger, J., Fendler, W. P., Herrmann, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06163-x · Cited by 19 · see citing works

[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

Privé, B. M., Noordzij, W., Muselaers, S., de Jong, I. J., van Oort, I. M., Janssen, M. J. R., van Rijk, M. C., van Gemert, W. A., Timmermans, B. J. R., de Groot, M., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00762-4 · Cited by 18 · see citing works

Prognostic Implications of PET-Derived Tumor Volume and Uptake in Patients with Neuroendocrine Tumors

Weber, M., Telli, T., Kersting, D., & Seifert, R. (2023) · Cancers · doi:10.3390/cancers15143581 · Cited by 18 · see citing works

Real-World Experience with177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Tuchayi, A. M., Yadav, S., Jiang, F., Kim, S. T., Saelee, R., Morley, A., Juarez, R., Lawhn-Heath, C. A., Wang, Y., de Kouchkovsky, I., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266842 · Cited by 18 · see citing works

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects

Szidonya, L. K., Barwick, T. D., Challapalli, A., Naik, M., Eccles, A., Barbon, D. A., & Mallak, N. (2024) · Radiographics · doi:10.1148/rg.240080 · Cited by 18 · see citing works

Clinical Implementation of177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

Ravi, P. K., Whelpley, B., Kelly, E., Wolanski, A., Ritzer, J., Robertson, M., Shah, H., Morgans, A. K., Wei, X. X., Sunkara, R., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265194 · Cited by 18 · see citing works

Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic Castration-resistant prostate cancer

Zang, S., Meng, Q., Li, X., Guo, T., Zhang, L., Zhao, Z., Yu, F., Zhang, P., Wu, W., Ni, Y., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07628-x · Cited by 16 · see citing works

Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): An international multicenter study

Gafita, A., Rauscher, I., Weber, M., Hadaschik, B., Wang, H., Armstrong, W. R., Tauber, R. L., Grogan, T. R., Czernin, J., Rettig, M. B., et al. (2022) · European Urology · doi:10.1016/s0302-2838(22)00611-x · Cited by 16 · see citing works

Management of bone metastasis in prostate cancer

Nishimura, K. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01435-w · Cited by 16 · see citing works

Nuclear medicine theranostics comes of age

Herrmann, K., Krause, B. J., Hadaschik, B. A., Kunikowska, J., van Poppel, H., N'Dow, J. M., Sartor, O., & Oyen, W. J. G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00540-4 · Cited by 16 · see citing works

Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac]Ac-PSMA and Its Relevance Compared with [177Lu]Lu-PSMA in Advanced Prostate Cancer Management

Jalloul, W., Ghizdovăţ, V., Pócza, T., Saviuc, A. I., Jalloul, D., Grierosu, I. C., & Ștefănescu, C. (2025) · Pharmaceuticals · doi:10.3390/ph18081215 · Cited by 16 · see citing works

PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives

Sandhu, K., Chen, D. C., Hennes, D. M. Z. B., Murphy, D. G., Lawrentschuk, N., & Perera, M. (2025) · Cancers · doi:10.3390/cancers17223717 · Cited by 15 · see citing works

Dual-Time-Point Posttherapy177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome

Straub, M., Kupferschläger, J., Serna-­Higuita, L. M., Weissinger, M., Dittmann, H., la Fougère, C. J., & Fiz, F. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264770 · Cited by 15 · see citing works

Standardized PSMA-PET Imaging of Advanced Prostate Cancer

Seifert, R., Gafita, A., Telli, T., Voter, A. F., Herrmann, K., Pomper, M. G., Hadaschik, B. A., Rowe, S. P., & Fendler, W. P. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.07.005 · Cited by 15 · see citing works

[177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy

Lu, Q., Long, Y., Gai, Y., Liu, Q., Jiang, D., & Lan, X. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06155-x · Cited by 15 · see citing works

Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study

Pan, J. G., Zhang, T., Chen, S., Bu, T., Zhao, J., Ni, X., Shi, B., Gan, H., Yu, W., Wang, Q., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220506 · Cited by 15 · see citing works

Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions

Bent, E. H., & Morris, M. J. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01686-y · Cited by 14 · see citing works

First Safety and Efficacy Data with the Radiohybrid177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer

Dierks, A., Gäble, A., Rinscheid, A., Wienand, G., Pfob, C. H., Kircher, M., Enke, J. S., Janzen, T., Patt, M., Trepel, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266741 · Cited by 14 · see citing works

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Chi, K. N., Yip, S., Bauman, G. S., Probst, S., Emmenegger, U., Kollmannsberger, C., Martineau, P., Niazi, T. M., Pouliot, F., Rendon, R. A., et al. (2024) · Current Oncology · doi:10.3390/curroncol31030106 · Cited by 14 · see citing works

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

Gafita, A., Martin, A. J., Emmett, L., Eiber, M., Iravani, A., Fendler, W. P., Buteau, J. P., Sandhu, S. K., Azad, A., Herrmann, K., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.03.009 · Cited by 14 · see citing works

Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐center prospective observational study

Telli, T., Tuncel, M., Karabulut, E., Aksoy, S., Erman, M., Akdoğan, B., & Çağlar, M. (2023) · The Prostate · doi:10.1002/pros.24518 · Cited by 14 · see citing works

Innovation in Radionuclide Therapy for the Treatment of Prostate Cancers: Radiochemical Perspective and Recent Therapeutic Practices

Deshayes, E., Fersing, C., Thibault, C., Roumiguié, M., Pourquier, P., & Houédé, N. (2023) · Cancers · doi:10.3390/cancers15123133 · Cited by 14 · see citing works

The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy

Murthy, V., Ludwig, V. B., Gafita, A., Hope, T. A., & Calais, J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268818 · Cited by 13 · see citing works

Development and Validation of Nomograms to Predict Cancer-Specific Survival and Overall Survival in Elderly Patients With Prostate Cancer: A Population-Based Study

Zhang, Z., Zhanghuang, C., Wang, J., Tian, X., Wu, X., Li, M., Mi, T., Liu, J., Jin, L., Li, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.918780 · Cited by 13 · see citing works

PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy

Hartrampf, P. E., Serfling, S. E., Michalski, K., Buck, A. K., & Werner, R. A. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.06.003 · Cited by 13 · see citing works

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radioligand Therapy

Gaal, S., Huang, K., Rogasch, J. M. M., Jochens, H. V., Santis, M. D., Erber, B., & Amthauer, H. (2023) · Cancers · doi:10.3390/cancers15204907 · Cited by 13 · see citing works

Predicting the risk category of thymoma with machine learning-based computed tomography radiomics signatures and their between-imaging phase differences

Liang, Z., Li, J., Tang, Y.-H., Zhang, Y., Chen, C.-Y., Li, S., Wang, X., Xu, X., Zhuang, Z., He, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-69735-3 · Cited by 12 · see citing works

State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer

Abida, W. M., Beltran, H., & Raychaudhuri, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473636 · Cited by 12 · see citing works

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study

Karpinski, M. J., Civan, C., Rauscher, I., Güven, O., Eiber, M., Hoberück, S., Miederer, M., Bundschuh, R. A., Hölscher, T., Calais, J., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00016-1 · Cited by 11 · see citing works

Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy

Hartrampf, P. E., Mihatsch, P. W., Seitz, A. K., Sólnes, L. B., Rowe, S. P., Pomper, M. G., Kübler, H. R., Bley, T. A., Buck, A. K., & Werner, R. A. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265379 · Cited by 11 · see citing works

Heterogeneity of [68Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response

Pan, J. G., Zhao, J., Ni, X., Zhu, B., Hu, X., Wang, Q., Yu, W., Zhang, T., Gan, H., Wang, B., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06123-5 · Cited by 11 · see citing works

Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?

Vetrone, L., Fortunati, E., Castellucci, P., & Fanti, S. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.06.004 · Cited by 11 · see citing works

Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study)

Chua, W. M., Lam, W. W.-C., Tong, A. K. T., Sultana, R., Kua, S. M. Y., Kanesvaran, R., Wong, A. S. C., Tay, K. J., Cheng, T. J. L., Ng, D. C. E., et al. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13944 · Cited by 10 · see citing works

Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer

Hindié, E. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00542-8 · Cited by 2 · see citing works

Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International StudyPreprint

Gafita, A., Calais, J., Grogan, T., Zeldin, A., Hadaschik, B. A., Wang, H., Weber, M., Sandhu, S. K., Kratochwil, C., Esfandiari, R., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3798566 · Cited by 1 · see citing works

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

Herrmann, K., Gafita, A., Bono, J. S. D., Sartor, O., Chi, K. N., Krause, B. J., Rahbar, K., Tagawa, S. T., Czernin, J., El-Haddad, G. E., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102862 · Cited by 37 · see citing works

Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.

Herrmann, K., Gafita, A., Bono, J. S. D., Sartor, O. A., Chi, K. N., Krause, B. J., Rahbar, K., Tagawa, S. T., Czernin, J. G., El-Haddad, G. E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.5028 · Cited by 4 · see citing works

Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Kafka, M., Horninger, A., di Santo, G., Virgolini, I. J., Neuwirt, H., Unterrainer, L. M., Kunte, S. C., Deiss, E., Paffenholz, P., Heidenreich, A., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.07.018 · Cited by 34 · see citing works